Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P62244

UPID:
RS15A_HUMAN

ALTERNATIVE NAMES:
40S ribosomal protein S15a

ALTERNATIVE UPACC:
P62244; P39027; P39031; Q3MHD9; Q8C023; Q9BV24

BACKGROUND:
The protein Small ribosomal subunit protein uS8, alternatively named 40S ribosomal protein S15a, is integral to the small ribosomal subunit's formation. It assists in the nascent pre-rRNA's processing within the nucleolus, contributing to RNA folding and modifications. This protein's function is vital for effective erythropoiesis, highlighting its significance in the cellular machinery.

THERAPEUTIC SIGNIFICANCE:
Small ribosomal subunit protein uS8's involvement in Diamond-Blackfan anemia 20, characterized by macrocytic anemia and increased malignancy risk, underscores its potential as a therapeutic target. Exploring the function of Small ribosomal subunit protein uS8 could lead to innovative treatments for this anemia and possibly other erythropoiesis-related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.